Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E14.50 EPS (ttm)10.56 Insider Own0.20% Shs Outstand742.21M Perf Week-4.34%
Market Cap113.57B Forward P/E12.05 EPS next Y12.69 Insider Trans0.00% Shs Float734.06M Perf Month-4.61%
Income7.89B PEG2.66 EPS next Q3.10 Inst Own81.10% Short Float1.08% Perf Quarter-11.62%
Sales22.93B P/S4.95 EPS this Y13.10% Inst Trans0.20% Short Ratio2.22 Perf Half Y3.84%
Book/sh41.57 P/B3.68 EPS next Y1.89% ROA10.20% Target Price182.87 Perf Year1.89%
Cash/sh51.73 P/C2.96 EPS next 5Y5.45% ROE26.00% 52W Range133.64 - 184.21 Perf YTD4.66%
Dividend4.60 P/FCF16.50 EPS past 5Y20.50% ROI13.00% 52W High-16.93% Beta1.38
Dividend %3.01% Quick Ratio4.10 Sales past 5Y8.10% Gross Margin81.90% 52W Low14.50% ATR2.18
Employees19200 Current Ratio4.40 Sales Q/Q-1.10% Oper. Margin43.50% RSI (14)22.39 Volatility1.32% 1.19%
OptionableYes Debt/Eq1.11 EPS Q/Q11.80% Profit Margin34.40% Rel Volume1.93 Prev Close156.51
ShortableYes LT Debt/Eq0.99 EarningsApr 26 AMC Payout39.00% Avg Volume3.58M Price153.02
Recom2.40 SMA20-5.40% SMA50-7.14% SMA200-5.35% Volume6,910,049 Change-2.23%
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
May-22-17 05:54PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Amgen Inc. Business Wire
04:48PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN PR Newswire
04:09PM  Radius Health Spikes 20% After Amgen Osteoporosis Drug Derailed Investor's Business Daily
03:43PM  Amgen Can Shrug Off Its Bone-Drug Risks Bloomberg
03:43PM  Amgen osteoporosis drug imperiled by safety concerns CNBC Videos
02:30PM  Amgen's Woes: It Could Always Be Worse! Investopedia
01:26PM  Defense in the Trader Blitz CNBC Videos
01:23PM  Here's Why Radius Health Gained as Much as 20.2% Today Motley Fool
12:57PM  [$$] Another Gloomy Day for Amgen The Wall Street Journal
12:49PM  Technology and defense companies lead US stocks higher Associated Press
10:57AM  [$$] Safety risk for Amgen and UCB's bone drug lifts rival Radius Financial Times
10:28AM  UPDATE: Amgen Inc. stock drops 2% on drug's cardiovascular risk; no approval expected this year MarketWatch
10:14AM  Amgen: Another One Bites the Dust? Barrons.com
09:44AM  Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In TheStreet.com
09:43AM  Like A Spycam Peeking Into Fidelity Stock Moves, This Info Can Pump Up Your Retirement Account Investor's Business Daily
09:42AM  Biotech Movers: Radius Health, Amgen, Paratek TheStreet.com
09:38AM  Amgen's Bone Drug Disappointment Shows Limits Of Genetics In Drug Discovery Forbes
08:52AM  Amgen Evenity Approval Derailed on Cardiovascular Side Effect Zacks
08:52AM  Morning Movers: Ford Flies, Lockheed Leaps, Amgen Slumps Barrons.com
08:42AM  The 3 Best Dividend Stocks in Arthritis Medication Motley Fool
07:43AM  Early movers: F, HUN, RBS, AMGN, PPG, BA, BX & more CNBC
05:01AM  UCB Stock Plunges After Trials Reveal Safety Risk in Amgen JV TheStreet.com
May-21-17 08:56PM  Higher rate of heart problems seen with Amgen bone drug in trial Reuters
07:05PM  Higher rate of heart problems with Amgen osteoporosis drug in trial Reuters
06:28PM  Higher rate of heart problems with Amgen osteoporosis drug in trial Reuters
06:00PM  Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY (Romosozumab) In Postmenopausal Women With Osteoporosis PR Newswire
May-20-17 03:05PM  Repatha® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets PR Newswire
May-19-17 05:06PM  Amgen Announces Voting Results of Annual Meeting of Stockholders PR Newswire
04:48PM  Industry News And Stocks To Watch Investor's Business Daily
04:30PM  Amgen, Gilead, Biogen Won't Lead The Biotech Boom So Who Will? Investor's Business Daily
01:09PM  5 Reasons Big Biotech Could Gain 25%-30% Barrons.com
12:02PM  Why Stay Bullish On Gilead Barrons.com
10:20AM  Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab Zacks
May-18-17 11:49AM  Amgen, Inc. : AMGN-US: Dividend Analysis : May 17th, 2017 (record date) : By the numbers : May 18, 2017 Capital Cube
09:23AM  AbbVie Down on Humira Patent Loss: Is More Damage in Store? Zacks
09:00AM  Amgen Submits Biologics License Application To The FDA For Erenumab PR Newswire
May-17-17 05:02PM  AbbVie Loses Key Humira Patent In Battle With Small-Cap Biotech Investor's Business Daily
05:00PM  Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio PR Newswire
10:14AM  AbbVie: Losing Humira Patent Isn't The End Barrons.com
May-16-17 03:42PM  3 Best Dividend Stocks in Biotech Motley Fool
May-15-17 07:06PM  Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint Zacks
03:13PM  ETFs with exposure to Amgen, Inc. : May 15, 2017 Capital Cube
09:30AM  The Zacks Analyst Blog Highlights: J.C. Penney, Amazon, Verizon, Citigroup and Amgen Zacks
May-14-17 09:03AM  Better Buy: Gilead Sciences, Inc. vs. Amgen Inc. Motley Fool
May-12-17 05:00PM  Johnson & Johnson Analyst Day Yahoo Finance Video
04:20PM  Can Teva Hold Its Own In Bringing Migraine Drugs To Market? Investor's Business Daily
04:00PM  Amgen To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference PR Newswire
01:28PM  Stock Market Today & Weak Retail Earnings Zacks
12:04PM  Is Regeneron Pharmaceuticals Stock Still a Buy After Its Big Bounce? Motley Fool
09:14AM  Lilly migraine treatment meets main goal in late-stage studies Reuters
May-11-17 12:19AM  Asian stocks mostly higher in quiet trading; oil prices gain Associated Press
May-10-17 10:40AM  Major Biotech Short Interest Remains Mixed 24/7 Wall St.
May-09-17 08:55AM  Edited Transcript of AMGN earnings conference call or presentation 26-Apr-17 9:00pm GMT Thomson Reuters StreetEvents
May-08-17 09:51AM  Amgen Inc. -- Moody's rates Amgen's notes Baa1; stable outlook Moody's
May-07-17 07:22AM  Better Buy: Amgen Inc. vs. Johnson & Johnson Motley Fool
May-05-17 04:37PM  Will 'Comeback Kid' Regeneron Survive Amgen's Cholesterol Squeeze? Investor's Business Daily
May-04-17 03:40PM  ETFs with exposure to Amgen, Inc. : May 4, 2017 Capital Cube
05:00AM  Big Pharma Losing Leverage as Payers Raise Pressure on Price Bloomberg
May-03-17 02:48PM  New deals for drugs: No heart attack or your money back Associated Press
11:56AM  New deals for drugs: No heart attack or your money back Associated Press
10:59AM  Amgen, Inc. :AMGN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017 Capital Cube
08:53AM  Celgene vs. Amgen: Which Stock is a Better Pick Post Q1 Earnings? Zacks
07:22AM  Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update Zacks
May-02-17 06:35PM  In unique deal, Amgen offering full refund to Harvard Pilgrim if $14,000 drug fails American City Business Journals
01:15PM  Amgen's rough couple of days CNBC Videos
May-01-17 10:27PM  Temasek and Jack Ma-Backed Fund Invest in Genomics Business Bloomberg
06:48PM  Cramer's lightning round: Stick with this airline through its dip CNBC
10:33AM  Neurotrope Alzheimer's drug data fails to impress; shares crater Reuters
09:06AM  Enbrel Saw a Fall in Revenue in 1Q17 Market Realist
07:37AM  Prolia Continued to Lead in the Bone Health Segment in 1Q17 Market Realist
Apr-29-17 01:41PM  Amgen: The Bear Case From a Bull Motley Fool
08:03AM  Is Regeneron (Finally) Getting Back on Track? Motley Fool
Apr-28-17 10:37AM  Amgen Seeks Approval for Xgeva in Multiple Myeloma Indication Market Realist
09:08AM  Kyprolis Witnessed a Strong Growth Trend in 1Q17 Market Realist
08:55AM  Biotech Surge: How To Survive In A Volatile Market Investor's Business Daily
08:02AM  These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016 Motley Fool
07:39AM  Amgen Continues to Be Confident in Repatha in 2017 Market Realist
Apr-27-17 05:35PM  Analysts Recommendations for Amgen in April 2017 Market Realist
04:48PM  AbbVie Flirts With Buy Point After Q1 Earnings, Sales Top Investor's Business Daily
04:43PM  Celgene Dips On $95 Million Lag In Psoriasis Sales, But Earnings Top Investor's Business Daily
04:00PM  Amgen To Participate In The 2017 World Medical Innovation Forum Focused On Cardiovascular Disease PR Newswire
03:56PM  Amgen Reported a Small Fall in Revenue in 1Q17 Market Realist
03:51PM  Three Biotechs EnterOne Biotech Gains Barrons.com
12:07PM  Biopharma earnings bonanza CNBC Videos
11:24AM  Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline Zacks
10:33AM  NICE Recommends Amgen's BLINCYTO® (Blinatumomab) for Adults With Relapsed or Refractory Philadelphia Chromosome-Negative B-Precursor Acute Lymphoblastic Leukaemia PR Newswire
09:21AM  Amgen's Q1 Results Highlight the Need for an Acquisition Motley Fool
08:51AM  Biotech Earnings Roundup: Exact Sciences Flying Higher Investopedia
07:47AM  Early movers: CMCSA, LUV, F, DOW, RTN, BMY & more CNBC
07:39AM  Biogen Reports Strong Revenue Growth in 1Q17 Market Realist
Apr-26-17 08:23PM  Amgen Reports Mixed Financials Results as Its Lead Drug, Enbrel, Sees Sales Decrease TheStreet.com
07:02PM  Amgen Reports Mixed Financials Results as Its Lead Drug, Embrel, Sees Sales Decrease TheStreet.com
07:00PM  Evening Movers: Amgen Slumps, Weight Watchers Jumps, Las Vegas Sands Slips Barrons.com
06:35PM  Cost controls help offset lower Amgen first-quarter drug sales Reuters
05:41PM  Amgen CEO: Hopeful Trump administration can deliver tax r... CNBC Videos
05:36PM  After-hours buzz: PYPL, AMGN, FFIV & more CNBC
05:28PM  Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top Investor's Business Daily
04:24PM  Amgen tops 1Q profit forecasts Associated Press
04:21PM  Amgen shares slide on weak Enbrel sales MarketWatch
04:10PM  Amgen first-quarter profit exceeds Street estimates on lower costs Reuters
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM